Pulmonary Endarterectomy Safe, Effective
Surgery beneficial in CTEPH patients.

BY MITCHEL L. ZOLER
Elsevier Global Medical News

TORONTO — Nearly 400 patients with newly diagnosed chronic thromboembolic pulmonary hypertension underwent pulmonary endarterectomy with a low, 5% in-hospital mortality rate at 17 European centers.

“In specialized centers, the surgical management of incidentally newly diagnosed chronic thromboembolic pulmonary hypertension (CTEPH) provided favorable results as indicated by a low operative mortality and improvement of exercise capacity and hemodynamics,” Dr. Eckhard Mayer said at the annual meeting of the American Association for Thoracic Surgery.

“As low exercise capacity and high pulmonary vascular resistance are risk factors for survival, earlier diagnosis seems mandatory, and referral to pulmonary endarterectomy surgery at expert centers should not be delayed,” said Dr. Mayer, director of the department of thoracic surgery at the Kerkhoff Clinic in Bad Nauheim, Germany.

The 1-year mortality rate among the 386 patients who underwent pulmonary endarterectomy was 7%.

The European CTEPH registry began in 2006, and the current review included 679 patients diagnosed during February 2007-January 2009. All patients included in the review had been diagnosed within 6 months of entering the registry, and none had received treatment for pulmonary artery hypertension before the CTEPH diagnosis. All patients received at least 3 months of anticoagulation therapy.

The consulting surgeons determined that 427 of the 679 patients included in the review had been diagnosed within 6 months of entering the registry, and none had received treatment for pulmonary artery hypertension before the CTEPH diagnosis. All patients received at least 3 months of anticoagulation therapy.

Pulmonary Perspectives
Disparities in Health Care
Treatment of patients with AMI differs according to their location. • 12

RSV Prevention Under Review

BY SHARON WORCESTER
Elsevier Global Medical News

ATLANTA — In the wake of a recent Food and Drug Administration advisory panel vote against recommending licensure of a new drug for the prevention of respiratory syncytial virus, a Centers for Disease Control and Prevention working group on RSV immunoprophylaxis will continue to develop recommendations for the use of currently available products, the group’s chair said.

The new drug currently under FDA review is motavizumab (MedImmune/AstraZeneca), a humanized monoclonal antibody. The FDA advisory panel expressed concern that the drug has additional safety issues but no clear benefit over existing products on the market, Dr. Lance Chilton reported at a meeting of the CDC’s Advisory Committee on Immunization Practices. Efforts will continue to develop recommendations for prophylaxis, based on available evidence. See RSV • page 2

CRITICAL CARE INSTITUTE
American College of Chest Physicians

CRITICAL CARE
COMMENTARY
Today, ECMO is safer and easier to provide.
See page 9.
Procedure Has Low Mortality

Endarterectomy • from page 1

patients were operable, and 173 underwent surgery. The surgeons deemed the remaining 252 patients inoperable, despite the 13 who had surgery.

The median age of the 386 surgery patients was 60, and 54% were men. The average time from their first symptoms until diagnosis was 15 months, and 80% had a patent of acute pulmonary embolism. Their median pulmonary artery pressure at rest was 48 mm Hg, and median pulmonary vascular resistance (PVR) at rest was 728 dyn/sec/cm². About a quarter of the patients received treatment for pulmonary artery hypertension following the diagnosis.

The surgical technique used followed the approach developed at the University of California, San Diego, with complete endarterectomy done in 358 patients; 143 received a perioperative venous caval filter. During surgery, patients spent a median of 35 minutes in deep hypotensive circulatory arrest.

Surgical complications occurred in 49% of the patients. The most common complications included infection in 19%, persistent pulmonary hypertension in 17%, and neurologic complications in 11%. Several patients had more than one complication.

A multivariate regression analysis identified two baseline risk factors with a statistically significant link to mortality. PVR at baseline was associated with both in-hospital and 1-year mortality. Patients with a baseline PVR of less than 400 dyn/sec/cm² had no increase in in-hospital mortality and a 2% increase in 1-year mortality, compared with those with a baseline PVR of 1,200 dyn/sec/cm², who had a significant 11% increase in in-hospital and a 13% increase in 1-year mortality. Each 100 dyn/sec/cm² increase in PVR boosted the in-hospital mortality rate by 79% and the 1-year mortality rate by 40%.

Six-minute walk distance was tied to 1-year mortality only. Each 100-m additional distance walked in 6 minutes reduced the 1-year mortality rate by 60%. Patient volume at individual centers also showed a relationship with mortality, but the differences among the various main-stream treatment centers with cardiothoracic surgeons and supporting subspecialists experienced in the care of patients during and after this procedure in the United States are currently recapitulating the outcomes seen in this European registry. Clearly, more exposure and information about the technique among physicians caring for patients with CTEPH will enhance physicians’ knowledge about management of this disorder and referral to centers that provide this service.

CDC Drafting Recommendations

RSV • from page 1

information on disease burden, safety, efficacy, and economics, said Dr. Chilton, chair of the RSV immunoprophylaxis working group and a pediatrician with the Young Children’s Health Center at the University of New Mexico, Albuquerque.

RSV is the leading cause of lower respiratory tract illness in infants and young children, and currently there is no vaccine available. Dr. Chilton said, noting that efforts to develop a vaccine are ongoing, and “when it comes, it will change the face of pediatrics.”

Until then, preventive treatment is available in the form of palivizumab—a safe and effective product for immunoprophylaxis, according to Dr. Chilton. However, the drug is expensive, with an estimated cost of nearly $6,700 per patient per year, and guidelines for appropriate use are needed, he said.

Efforts to Develop a Vaccine Are Ongoing, and ‘When It Comes, It Will Change the Face of Pediatrics.’

Dr. Chilton said the working group’s efforts to develop such guidelines will include:

- A review of the epidemiology of RSV infection, including seasonality and host and environmental risk factors for severe disease.
- An assessment of the safety and efficacy of prophylaxis.
- Identification of the areas requiring further research for informing recommendations.
- Drafting of recommendations for ACIP consideration.

Up to 125,000 hospitalizations for RSV occur in the United States each year, with the highest incidence in young infants, and with a disproportionate burden among those with lung disease, heart disease, or prematurity.

The FDA is currently scheduled to review the biologics licensing application for motavizumab this month. Dr. Chilton reported that he has no financial conflicts of interest relevant to his presentation.
Hospital infection reports provide limited data regarding care and mortality.

BY CRAIG GUILLOT
Elsevier Global Medical News

New Orleans — A hospital's reported rate of infections acquired in the intensive care unit may not be an indication of ICU mortality risk.

The finding that these publicly reported infection rates often are not tied to patient outcomes shows that the data can be misleading and may not be a measure of overall ICU performance, according to researchers who conducted a retrospective study presented at an international conference of the American Thoracic Society.

The study included 158 hospitals in Pennsylvania linked in 2006 to the state Department of Health's 30-day mortality data. The data included 18,444 ICU admissions involving mechanical ventilation and 16,285 admissions involving central venous catheterization.

Within the two cohorts, the data were extrapolated to derive a risk-adjusted ICU mortality rate for every hospital in the analysis, which controlled for variables such as severity of illness, age, and gender, reported Dr. Kate Courtwright of the University of Pennsylvania, Philadelphia.

The results showed no correlation between risk-adjusted mortality and publicly reported ICU infection rates. Many hospitals with few pneumonia or catheter-associated bloodstream infections had higher ICU mortality than did hospitals with high infection rates. The 43 hospitals that reported no cases of ICU-acquired pneumonia had a mortality rate of 35.7% for patients on mechanical ventilation, but hospitals with high infection rates (18 infections per 1,000 ventilator-days) had an average mortality of 34.6%.

Median risk-adjusted mortality was 26.9% for catheterized patients and 35.1% for ventilated patients. Linear regression models adjusting for hospital size and academic status, higher ventilator-associated pneumonia rates were associated with higher risk-adjusted mortality in ventilated patients.

Similarly, higher catheter-related bloodstream infection rates were not associated with higher risk-adjusted mortality in catheterized patients, reported Dr. Courtwright.

"We found there was essentially zero correlation in the mechanical ventilation cohort and catheter group of patients. There wasn't even a trend," she said.

Health care-associated infections (HAIs) affect 5%-10% of hospitalized patients in the United States, resulting in an estimated 90,000 deaths annually. Public reporting of HAI rates has increased in recent years, and 29 states now have mandatory reporting laws, Dr. Courtwright said.

The commonly held but unproven assumption has been that hospitals with lower rates of HAIs have higher quality of care and lower patient mortality. But this study showed that hospital infection reports provide limited data regarding quality of care and mortality, she said.

Many hospitals with otherwise good report cards may have high mortality, and thus many good performers may be penalized for their reported infection rates. This is especially important because infection rates will be used as a measure for hospital reimbursement and "pay for performance" incentives under health care reform.

This study "really challenged a commonly held assumption. Many performance initiatives are based on public data, and using these report cards to choose a hospital may be misleading and harmful," she said.

Dr. Courtwright reported no conflicts of interest.

Integrating Care
Palliative • from page 1

The goal here is to make this a routine part of critical care practice across the full range of ICUs.

Instead, the better communication fostered by using palliative care strategies results in a reduced use of non-beneficial ICU treatments and even a decrease in the stay. "It cuts back on delay and improves communication," Dr. Nelson said.

Right now, the biggest barrier is convincing people to let go of the old model of sequential care, Dr. Nelson said. In that model, a patient receives aggressive care in the ICU and, when that is exhausted, moves to palliative care in a hospice setting.

"There's a fear that the introduction of palliative care early on means that the intensive care will somehow be diminished, she noted. "That's not necessary, and it's not optimal," Dr. Nelson explained. When done right, palliative care should support an aggressive care plan by making sure it is tailored to the patient's needs and desires. Palliative care can also help identify untreated pain and other symptoms.

Over the last decade, palliative care programs in general have spread across the country and increasingly been embraced by physicians. Dr. Nelson said she hopes that palliative care in the ICU setting will have similar success. "The goal here is to make this a routine part of critical care practice across the full range of ICUs," she said.

The concept of palliative care in the ICU is already catching on, noted Dr. J. Randall Curtis, FCCP, professor of medicine at the University of Washington and academic status, higher ventilator-associated pneumonia rates were associated with higher risk-adjusted mortality in ventilated patients.

Similarly, higher catheter-related bloodstream infection rates were not associated with higher risk-adjusted mortality in catheterized patients, reported Dr. Courtwright.

"We found there was essentially zero correlation in the mechanical ventilation cohort and catheter group of patients. There wasn't even a trend," she said.

Health care-associated infections (HAIs) affect 5%-10% of hospitalized patients in the United States, resulting in an estimated 90,000 deaths annually. Public reporting of HAI rates has increased in recent years, and 29 states now have mandatory reporting laws, Dr. Courtwright said.

The commonly held but unproven assumption has been that hospitals with lower rates of HAIs have higher quality of care and lower patient mortality. But this study showed that hospital infection reports provide limited data regarding quality of care and mortality, she said.

Many hospitals with otherwise good report cards may have high mortality, and thus many good performers may be penalized for their reported infection rates. This is especially important because infection rates will be used as a measure for hospital reimbursement and "pay for performance" incentives under health care reform.

This study "really challenged a commonly held assumption. Many performance initiatives are based on public data, and using these report cards to choose a hospital may be misleading and harmful," she said.

Dr. Courtwright reported no conflicts of interest.

The goal here is to make this a routine part of critical care practice across the full range of ICUs.

Similarly, higher catheter-related bloodstream infection rates were not associated with higher risk-adjusted mortality in catheterized patients, reported Dr. Courtwright.

"We found there was essentially zero correlation in the mechanical ventilation cohort and catheter group of patients. There wasn't even a trend," she said.

Health care-associated infections (HAIs) affect 5%-10% of hospitalized patients in the United States, resulting in an estimated 90,000 deaths annually. Public reporting of HAI rates has increased in recent years, and 29 states now have mandatory reporting laws, Dr. Courtwright said.

The commonly held but unproven assumption has been that hospitals with lower rates of HAIs have higher quality of care and lower patient mortality. But this study showed that hospital infection reports provide limited data regarding quality of care and mortality, she said.

Many hospitals with otherwise good report cards may have high mortality, and thus many good performers may be penalized for their reported infection rates. This is especially important because infection rates will be used as a measure for hospital reimbursement and "pay for performance" incentives under health care reform.

This study "really challenged a commonly held assumption. Many performance initiatives are based on public data, and using these report cards to choose a hospital may be misleading and harmful," she said.

Dr. Courtwright reported no conflicts of interest.
Early Palliative Care Boosts Lung Cancer Survival

BY CRAIG GUILLOT
Elsivier Global Medical News

NEW ORLEANS — Long-term treatment with the monoclonal antibody omalizumab reduced the rate of asthma exacerbations by 25% in a phase IIIb, randomized, controlled trial of 850 patients with moderate to severe allergic asthma. Researchers at five U.S. medical centers recruited patients, aged 12-75 years, who had had at least one asthma exacerbation in the past 12 months despite treatment with long-acting beta-agonists and an inhaled corticosteroid. The researchers added omalizumab (Xolair) to those medications in 427 study participants and placebo in 423. Omalizumab (150-375 mg) or placebo was administered subcutaneously every 2-4 weeks, with dosage and frequency determined by body weight and baseline serum total immunoglobulin E.

The primary outcome of the trial was the rate of asthma exacerbations during the 48 weeks of treatment with evaluable data. Secondary outcomes included asthma symptom scores, asthma-related quality of life, and the daily number of puffs of rescue albuterol needed. Of the 79% of recruits who completed the study, those receiving omalizumab had a rate of exacerbations of 0.66 at 48 weeks, while patients who received the placebo had a rate of 0.88, the team reported at an international conference of the American Thoracic Society.

The omalizumab patients also had a greater improvement in asthma-related quality of life questionnaire scores, compared with placebo (1.15 vs. 0.92). While the mean number of rescue puffs per day and mean asthma exacerbations were similar, those two measures favored omalizumab. The most common adverse events in both the placebo and omalizumab groups were related to bleeding. There was one death in the placebo group due to cardiac arrest. The percentage of serious adverse events was similar: 10.5% for placebo and 9.3% for omalizumab. The current standard of care for patients with allergic asthma who do not respond well to inhaled corticosteroids is to add a long-acting beta-agonist or other medication. While previous clinical trials had suggested that omalizumab could be effective for these patients, the new trial “demonstrates that long-term treatment with omalizumab is safe and can significantly reduce the rate of asthma exacerbations . . . in patients with poorly controlled moderate to severe allergic asthma, despite receiving aggressive asthma controller therapy,” the researchers concluded.

“This group did respond, and I think very selectively enrolling people who are on high doses of inhaled corticosteroid can validate the recommendations,” said study coauthor Dr. William Busse, a professor of medicine at the University of Wisconsin, Madison.

The trial was funded by Genentech, a wholly owned member of the Roche Group. Dr. Busse disclosed that in the past 3 years he received consul tancy assignments, advisory board appointments, and grants from several large firms, including Novartis, AstraZeneca, GlaxoSmithKline, Pfizer, and Merck & Co.
Some patients have ZYVOX written all over them

ZYVOX is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms:

Nosocomial pneumonia caused by *Staphylococcus aureus* (methicillin-susceptible and -resistant strains) or *Streptococcus pneumoniae* (including multidrug-resistant strains [MDRSP]).

Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by *Staphylococcus aureus* (methicillin-susceptible and -resistant strains), *Streptococcus pyogenes*, or *Streptococcus agalactiae*. ZYVOX has not been studied in the treatment of decubitus ulcers.

ZYVOX use is contraindicated in patients with known hypersensitivity to linezolid or any of the other product components.

ZYVOX should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g. phenelzine, isocarboxazid) or within 2 weeks of taking any such product.

Unless patients are monitored for potential increases in blood pressure, ZYVOX should not be administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following: directly and indirectly acting sympathomimetic, vasopressor, and dopaminergic agents.

Unless patients are carefully observed for signs and/or symptoms of serotonin syndrome, ZYVOX should not be administered to patients with carcinoid syndrome and/or patients taking any of the following medications: serotonin reuptake inhibitors, tricyclic antidepressants, serotonin 5-HT1 receptor agonists, meperidine, or buspirone.

Spontaneous reports of serotonin syndrome have been reported with the coadministration of ZYVOX and serotonergic agents. If signs or symptoms of serotonin syndrome, such as cognitive dysfunction, hyperthermia, hyperreflexia, and incoordination occur, discontinuation of one or both agents should be considered.

Myelosuppression (including anemia, leukopenia, pancytopenia, and thrombocytopenia) has been reported in patients receiving ZYVOX. In cases where the outcome is known, when ZYVOX was discontinued, the affected hematologic parameters returned to pretreatment levels. Complete blood counts should be monitored weekly, particularly in patients who receive ZYVOX for longer than 2 weeks.

ZYVOX is not approved and should not be used for the treatment of patients with catheter-related bloodstream infections or catheter-site infections.

ZYVOX has no clinical activity against Gram-negative pathogens and is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected.

Clostridium difficile associated diarrhea has been reported with use of nearly all antibacterial agents, including ZYVOX, and may range in severity from mild diarrhea to fatal colitis.

Lactic acidosis has been reported with the use of ZYVOX. Patients receiving ZYVOX who develop recurrent nausea, vomiting, unexplained acidosis, or a low bicarbonate level should receive immediate medical evaluation.

Peripheral and optic neuropathy have been reported primarily in patients treated with ZYVOX for longer than the maximum recommended duration of 28 days. If patients experience symptoms of visual impairment, prompt ophthalmic evaluation is recommended.

Convulsions have been reported in patients treated with ZYVOX. In some of these cases, a history of seizures or risk factors for seizures was reported.

The most commonly reported adverse events in adults across phase 3 clinical trials were diarrhea, nausea, and headache.

*methicillin-resistant Staphylococcus aureus*

References:

Please see www.zyvox.com for further information.
Biopsy Data Shed Light on Chemoresistant Lung Cancer

BY SARA FREEMAN

PARIS — Alterations in the expression of a well-known cancer gene called Myc may explain why some patients with non-small cell lung cancer are resistant to the effects of platinum-based chemotherapy.

The first results of a gene expression profiling analysis of NSCLC samples, taken prospectively from patients during the BATTLE trial, were presented at the Worldwide Innovative Networking in Personalized Cancer Medicine Symposium. “Myc is downregulated in treatment-refractory patients of the phase II BATTLE (Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination) trial were reported recently at the American Association for Cancer Research meeting. These results are consistent with the report that selecting treatment based on a patient’s individual tumor characteristics was not only feasible, but also improved patient outcomes.”

“This is a new kind of trial,” Dr. Saintigny said. “It is biopsy driven, and patients had a mandatory biopsy with analysis of 10-15 biomarkers before inclusion in one of the four treatment arms.” The BATTLE trial involved 255 patients who were randomly assigned to molecularly targeted treatment with erlotinib (Tarceva) alone or with chemotherapy.
values than many full-term neonates and older infants. Therefore, these preterm neonates should be included with a staging regimen of 10 mg/kg every 6 hours for 24 hours, followed by 5 mg/kg if the patient did not achieve a full-term birth. The neonates in this study who were treated with 10 mg/kg every 6 hours showed a significant improvement in birth weight and length compared to those treated with 5 mg/kg every 6 hours.

Dr. Saintigny observed that the expression of Myc in stage III/IV tumors was associated with sensitivity to cisplatin. He suggested that the expression of Myc and the underlying genetic abnormality be further explored.

The BATTLE data show that it is possible to target therapy according to the underlying genetic abnormality.

Dr. Hong commented that personalized therapy (or treatment tailored to the individual patient) has the potential to revolutionize care. He also expressed the hope that the results of the BATTLE project will be successful in improving outcomes for patients with advanced-stage lung cancer.

**8.6.2010 • CHEST PHYSICIAN**

CARDIOTHORACIC SURGERY

**AUGUST 2010 • CHEST PHYSICIAN**

Dr. Michael W. Conti, FACP, comments: "Personalized" therapy (or treatment tailored to the individual patient’s tumor characteristics) has been shown to be not only feasible but also successful in improving outcomes. This exciting and promising avenue of research has the potential to revolutionize the treatment of advanced-stage lung cancer.

**COMMENTARY**

Dr. Saintigny said that the role of antitumor agents that specifically target Myc may need to be reevaluated.

**REFERENCES**

3. BATTLE data show that it is possible to target therapy according to the underlying genetic abnormality. Chest. 2010;137(4):967-978.
4. Hong DK. Personalized therapy (or treatment tailored to the individual patient) has the potential to revolutionize care. Chest. 2010;137(4):967-978.

**8.6.2010 • CHEST PHYSICIAN**

CARDIOTHORACIC SURGERY

**AUGUST 2010 • CHEST PHYSICIAN**

Dr. Michael W. Conti, FACP, comments: "Personalized" therapy (or treatment tailored to the individual patient’s tumor characteristics) has been shown to be not only feasible but also successful in improving outcomes. This exciting and promising avenue of research has the potential to revolutionize the treatment of advanced-stage lung cancer.

**COMMENTARY**

Dr. Saintigny said that the role of antitumor agents that specifically target Myc may need to be reevaluated.

**REFERENCES**

3. BATTLE data show that it is possible to target therapy according to the underlying genetic abnormality. Chest. 2010;137(4):967-978.
4. Hong DK. Personalized therapy (or treatment tailored to the individual patient) has the potential to revolutionize care. Chest. 2010;137(4):967-978.
Online Education. Always Available.

Online education programs from the ACCP allow you to study pulmonary, critical care, and sleep medicine any time, anywhere. Take advantage of these FREE programs:

PCSSU Earn CME
New Name Reflects All Specialties
Each month, two lessons featuring current diagnostic information on pulmonary, critical care, or sleep medicine issues are posted to offer relevant updates. Study a lesson, complete its 10-question quiz, and earn one (1) AMA PRA Category 1 Credit™ for each lesson completed. Earn up to 240 credits for each volume.

CHESTSoudings® Earn CME
Link to video presentations featuring clinical updates in chest medicine, supplemented with references for further reading. Earn up to 0.5 AMA PRA Category 1 Credit™ for each presentation.

A Physician’s Perspective®
Watch video presentations of expert reviews, opinions, and summaries relevant to patient care and practice management strategies. Presentations are designed to enhance your clinical knowledge and patient care skills.

Case Puzzlers
Sharpen your clinical and diagnostic skills with ACCP case puzzles. Based on actual cases, ACCP case puzzles present rare or unusual cases and challenge you to make a diagnosis. Link to the correct answer with detailed discussion and recommended further reading.

Ambassadors Group Members Promote Lung Health

Ambassadors Group members, Monir Almassi, RN; and her daughter, Neda Almassi, organized the sixth annual 3K Walk/Run for Kids’ Lung Health on May 19, 2010, at Wisconsin Hills Middle School (WHMS) in Brookfield, WI. This is just one of two annual events that Mrs. Almassi organizes. Due to her efforts, sixth grade students at Pilgrim Park Middle School (PPMS) in Elm Grove, WI, attended their fourth annual 3K Walk/Run for Kids’ Lung Health on May 14, 2010. CHEST Foundation staff members Sue Ciesadlo and Teri Ruiz attended the WHMS event and saw firsthand how 320 sixth graders were kept involved while learning about lung health. Utilizing information provided in ‘The CHEST Foundation’s Lung Lessons® curriculums, two area high school students presented their ‘Lung Health’ presentation to the children. Following this, Mrs. Almassi recapped the major points and stressed to the children the importance of lung health.

Then it was time to begin the 3K Walk/Run held in the streets neighboring WHMS. Mrs. Almassi had coordinated with teachers, parents, and the Brookfield Police Department to help along the course. Upon completing the course, each student received a Love Your Lungs® wristband and a ‘Teens and Tobacco’ booklet from the Brookfield Police. Back inside, the children were able to get an up-close look at Mrs. Almassi’s pig lung demonstration of diseased vs healthy lungs. She also had a “jar of tar” for the students to see how a year’s worth of smoking pollutes the lungs. Mrs. Almassi answered questions and continued to stress the harmful effects of tobacco use.

The CHEST Foundation appreciates the dedication of Monir and Neda Almassi and their innovative use of the Lung Lessons® curriculums. Because of their efforts, the middle school children at WHMS and PPMS are actively engaged in lessons that give them memorable images and specific information about the dangers of smoking. Hopefully, these important messages will have a lifelong impact. The CHEST Foundation congratulates the Almassi family for establishing such an excellent lung health outreach tradition in their community. For more information about how you can implement an outreach program in your community, go to www.chestfoundation.org/foundation/ambassadors/tobacco.php.

From the CEO
Weaving the Work of the ACCP and The CHEST Foundation

I have the distinct honor to serve as an officer on The CHEST Foundation Board of Trustees. This experience with the philanthropic arm of the ACCP has been one of my most rewarding since becoming the Executive Vice President and CEO of the College last fall. At that time, ACCP leaders, staff, and I committed to advancing the College to the next level, including, and especially, The CHEST Foundation, which members have aptly described to me as the “soul of the ACCP.” The members understand that The Foundation, through its work in tobacco use prevention, humanitarian service, clinical research, and critical care/end-of-life care, adds an important human dimension to the College.

Specifically, the Board of Trustees sought to expand The CHEST Foundation fundraising base, with a measurable increase in donations. To that end, in January 2010, The Foundation engaged the consulting firm Cause Innovation to develop an innovative fundraising and branding initiative. The initiative consisted of four phases: (1) internal and external analyses; (2) brand analysis and enhancement strategy; (3) development of a master strategy; and (4) resource identification and execution.

To date, Cause Innovation, working collaboratively with CHEST Foundation staff and leadership, as well as with ACCP staff and leadership, has analyzed the resources and assets of the College and Foundation and crafted a master strategy. The firm conducted extensive and inclusive research to gain a thorough understanding of The Foundation and the ACCP and their relationship to one another and to our members. This phase included, but was not limited to, one-on-one interviews with leadership and an online survey of 1,000 members.

Based on its research and evaluation, Cause Innovation identified a need to break down walls between the ACCP and The CHEST Foundation. The ACCP Strategic Plan 2010 – 2011, which the Board of Regents approved at its June meeting, deliberately weaves the work of the ACCP and The Foundation together to strengthen the College as a whole by, for example, incorporating the funding initiatives of each into a single division. Similarly, The Foundation’s master strategy, which we are currently refining, will integrate The Foundation into the ACCP brand to create a more compelling position that provides platforms for cause marketing, drives innovative fundraising strategies, and increases member engagement.

Eighty-three percent of Americans believe that companies have a responsibility to help support causes, 72% of Americans want their employers to do more to support a cause or social issue, and 80% of Americans want companies to address health issues through cause marketing (2007 Cone Cause Evolution & Environmental Survey). These statistics suggest the enormous potential of “strategic cause alliances”—unique, integrated marketing strategies to engage consumers, employees, vendors/suppliers, and other stakeholders in raising funds for a cause, and in the case of The CHEST Foundation, to advance the prevention and treatment of chest diseases.

Keys to the success of The CHEST Foundation master strategy are the creation of a strategic architecture based on the attributes of The Foundation in the areas of education, care, and community; a microsite to establish a public face that leverages ACCP and Foundation assets related to patient education about the prevention of chest diseases; and a branding tag that telegraphs the work of The Foundation to stakeholders. The Foundation will unveil more about its master strategy, including an implementation plan, identification of resources, and timeline, in the coming months.

Stay tuned as we continue to propel the ACCP and The CHEST Foundation, together, to the next level and, in so doing, realize the enormous promise that The Foundation holds as the soul of your ACCP.

Mr. Markowski is Executive Vice President and Chief Executive Officer of the American College of Chest Physicians.
Extracorporeal membrane oxygenation (ECMO) is a technology that provides long-term cardiopulmonary bypass support for patients with the most severe but potentially reversible forms of respiratory and/or cardiovascular derangements. This technology has a long history in modern medicine and has become the standard of care for many childhood disorders. Early investigations of ECMO in the adult population demonstrated that it was an expensive, invasive modality that did not improve long-term outcome (Morriss et al. Am J Respir Crit Care Med. 1994;149[2 Pt 1]:295; Zapol et al. JAMA. 1979;242[21]:2193). However, more recent data suggest that ECMO has a place in the treatment of the adult patient with severe respiratory failure (Peek et al. Lancet. 2009;374[9698]:1351; Davies et al. JAMA. 2009;302[17]:1888). Advances in ECMO technology suggest that the time is right for a renaissance in adult ECMO use.

The technology behind the ECMO circuit is simple in concept. The essential components include a pump, oxygenator tubing, and vascular access (Fig 1). Each of the circuit components has undergone decades of refinement such that a modern ECMO circuit looks little like the systems of the past. Older circuits required frequent maintenance to the tubing to prevent malfunction, and the tubing was subject to occasional rupture or other catastrophic failure due to the roller pumps that were used. Constant attendance of the device by a trained technician was, therefore, mandatory. These problems limited ECMO use to a few centers and increased operational costs.

Recent advances in membrane and Manufacture of extracorporeal technologies have offered the opportunity to provide ECMO in a simplified and cost-effective manner. Such improvements include low resistance and highly reliable centrifugal pumps with minimal risk of failure. The older silicone-based oxygenators that suffered from regular plasma leak have been replaced by efficient, low-resistance polyurethane devices. The new generation of oxygenators operate at lower pressures than the older units, resulting in less hemolysis and lower circuit pressures. Importantly, the new oxygenators can support a patient for weeks without failure. bedside monitoring of anticoagulation using the activated clotting time point-of-care testing devices has been simplified with a shift to central lab-based activated partial thromboplastin times. Vascular access has also undergone considerable enhancements. ECMO circuitry initially involved accessing the venous and arterial circulation through open surgical exposure of venous and arterial vessels. Blood was extracted from the venous circulation, run through an oxygenator, and reinjected into a major artery, similar to cardiopulmonary bypass (Fig 1). Today, percutaneous techniques are commonly used for vascular access. The recent FDA approval of double-lumen adult venous cannulae (Fig 2) has simplified vascular access by allowing clinicians to use only a single venous (VV) cannula for support. These cannulae are designed to drain venous blood from the superior and inferior vena cava and then infuse highly oxygenated blood directly into the right atrium via a specially designed inflow port (Fig 1). This technique offers respiratory support with a reduced risk of ischemia and other complications associated with arterial-based access. Another advantage of the VV devices is their similarity to other large multilumen central venous catheters used in the ICU. The ECMO VV cannulae can be inserted by noninvasive strategies such as additional training, VV ECMO is now the preferred method of support for adult patients with acute respiratory failure.

All of these advances have made ECMO considerably simpler and safer. Although the technology still has a considerable level of complexity, it no longer requires a dedicated team to provide continuous support at the patient’s bedside. The modern ECMO system is simple enough that the nurse, with additional training on surveillance of the circuit and basic troubleshooting, can attend to both the patient and the ECMO circuit. Of course, this does not eliminate the need for the availability of knowledgeable and well-trained ECMO technicians. Such individuals are necessary to coordinate safe ECMO services, build and maintain ECMO systems, initiate and terminate ECMO support, and provide a higher level of ECMO troubleshooting than an ICU nurse could or should be expected to do.

Resistance to using ECMO for respiratory failure may linger from earlier and, arguably, no longer applicable studies. In 1979, 90 extraordinarily ill patients with severe ARDS were enrolled in an NIH-sponsored, randomized, prospective trial of VA ECMO vs standard mechanical ventilation (Zapol et al. JAMA. 1979;242[21]:2193). Forty-eight patients were managed using ECMO, and 42 received conventional ventilator support. The survival difference was not significant between the groups (9.5% vs 4.3%). A subsequent trial published by Morris and colleagues (Am J Respir Crit Care Med. 1994;149[2 Pt 1]:295) of 40 patients with severe ARDS, 21 of whom were randomized to ECMO for CO2 removal, showed no difference in survival between groups. While it is important to recognize that the early trials of ECMO did not show a survival benefit, it is also important to acknowledge how standard management of ARDS and the critically ill has evolved since these trials. Low tidal volume strategies, goal-directed sepsis management, DVT prophylaxis, and central line placement are all far different today than they were even 10 years ago. Expected mortality for a variety of critical illnesses ECMO support, and overall survival or severe disability at 6 months was 63% for the ECMO group vs 47% for the conventional management group. Appropriate criticisms of this study have focused on the lack of standardized management in the controls. Also, statistical significance was lost if patients from the ECMO center cohort who did not receive ECMO were removed. Many have reflected on CESAR as a trial of transfer of patients with severe ARDS to a comprehensive center with ECMO support rather than a trial of the ECMO technology itself.

However, the recent ECMO experiences with ARDS in the United Kingdom and severe respiratory failure due to influenza A(H1N1) have led to a renewed interest in using ECMO in adult respiratory failure. A report on ECMO and survival rates outside of the clinical trial environment was provided in JAMA (Davies et al. JAMA. 2009;302[17]:1888). In this study, conducted in Australia and New Zealand, 68 patients suffering from influenza A(H1N1) with ARDS and treated with ECMO were evaluated. The patient population in the ECMO cohort was exceptionally ill with a mean PaO2 to FiO2 ratio (P/F ratio) of 56 on an average of 18 cm H2O of positive end expiratory pressure prior to initiation of ECMO therapy.

Follow-up communication reported that 17 patients died in hospital (Furber et al. JAMA. 2010;304(1):941; author reply 942). Overall survival to hospital discharge among patients treated with ECMO was 75%—higher than reported with other series, which may reflect a population with fewer comorbidities and a single pathologic condition (Bardlett et al. JAMA. 2000;283(7):504).

ECMO today is far simpler and safer, and less technologic prowess and manpower are required at the bedside. In select populations, ECMO may provide a survival advantage in adults compared with traditional management. However, any institution interested in providing ECMO support must understand the high level of training and commitment required of all practitioners involved in the care of such patients. While ECMO is not considered the standard of care, recent advances suggest it is worthwhile to consider this approach when proven ventilation techniques are not adequate.

Dr James M. Blum; and Dr Andrew L. Rosenberg
Division of Critical Care
Department of Anesthesiology
University of Michigan Medical Center
Ann Arbor, MI
Cultural Diversity

Diversity is about knowledge, respect, compassion, and consideration. It is about taking the “me, myself, and I” out of the equation and replacing those words with otherness. The Cultural Diversity in Medicine NetWork mirrors the diversity of the ACCP. In recent years, the NetWork has focused on diversity-related issues in end-of-life care, racial disparities in lung cancer, Latino-Hispanic demographics and health systems utilization, humanitarian aid, home care in rural populations, and the effects of race, gender, socioeconomic status, and sexuality on the ethical practice of pulmonary and critical care medicine.

Diversity is everpresent also in the activities of The CHEST Foundation. In 2009, awards were distributed for projects in Peru, Bolivia, India, and Jordan, as well as the United States. This year, 2010, is The Year of the Lung, and the ACCP is partnering with other international organizations to raise global awareness of lung health, urging policy makers to increase research funding, enhance wellness programs, and support environmental and air quality legislation.

Diversity is obviously of importance when ACCP members reflect on health reform, communication, and access to care. Despite governmental funds devoted to studying and potentially correcting disparities, the economics of health care continue to create barriers to care. Diversity is the fabric of life. Culturally competent care requires that we nurture relationships with others in full recognition of our own potential biases and beliefs. As patient advocates, it is our responsibility to practice sensitively and knowledgeably, taking into account our cultural similarities, as well as differences. In the years ahead, the Cultural Diversity in Medicine NetWork intends to increase its membership and interact even more closely with other ACCP NetWorks. We hope you will join us at CHEST 2010 for our NetWork Open Meeting and Cultural Diversity in Medicine Luncheon. We invite you to let us know what we might do to assist you in your practices and educational endeavors by contacting the steering committee at networks@chestnet.org.

Home Care: Getting Your Medical Act Together and Taking It on the Road


Travel medical insurance is essential to safe, enjoyable travel. It provides coverage for medical expenses, including transportation to the hospital, physician services, hospital charges, operating rooms, and emergency medical evacuation. Most health insurance plans in the United States, including Medicare (with the exception of some supplemental plans), only cover patients domestically. When patients leave the country, they are without coverage. In the event of a medical emergency, obtaining treatment and hospital care in a foreign country can be very expensive. Medical “evacuations,” which may be required to get the traveler back home, can cost up to $50,000 or more.

Typically, travel insurance costs between 5% and 7% of the total trip cost. Researching the different plans is important, as they can vary greatly. Get a printed copy detailing exactly which emergency medical treatment and/or medical evacuation and transport services are provided. Ask about coverage for preexisting medical conditions and about policy riders that will transport you back to the hospital of your choice as opposed to the nearest hospital of their choice, which may still be in a foreign country or in a city far from home.

More information on this and other related travel topics will soon be available on the Home Care NetWork Web page at www.chestnet.org/accp/networks.

Barbara Rogers, NetWork Member; and Debra Karstadt, MA

Occupational and Environmental Health: Libby Asbestos and Beyond

Many physicians may consider “Libby asbestos” to be a problem limited to rural Montana and, as such, not germane to their practices. The ore (vermiculite) mined in Libby was initially milled in Libby and then transported to over 200 sites in the United States and Canada. The Environmental Protection Agency has estimated that 13 million US residents were exposed prior to 1990.

Once transported by rail, the vermiculite ore was “exfoliated” (otherwise known as expansion) by dropping the ore through a vertical furnace with exposure to temperatures as high as 850°C. The expanded or “popped” vermiculite was then bagged and sold for insulation, packing material, or as a soil additive.

Vermiculite ore mined in Libby was contaminated with amphibole (tremolite) asbestos at concentrations of up to 25% or more (Am Mineral. 2003;88:1955 and Kelly et al Inhale Toxicol. 2006;18[12]:941). As the ore was initially processed in Libby before shipment to the expansion plants, it is felt that the amphibole concentration in the processed ore (prior to expansion) was lower than that in the raw ore and that the shipped material contained amphibole asbestos in a concentration of 1% to 7% (US EPA Document 2000; 774-R-00-010). Kelly and colleagues (Inhale Toxicol. 2006;18[12]:941) described ambient air concentrations of 0.89 f/cc (1 h maximum) and personal air samples as high as 11.4 f/cc in a vermiculite expansion plant.

Similar to the experience in Witteenoen, Australia, and in the Italian asbestos cement industry, not only workers but also residents in areas to which the asbestos activity were exposed to amphibole fibers. Waste material was made available in dumps outside the processing plants, and children would play in the piles, with Kelly estimating that fiber exposure for the children was 1.4 f/cc. Kelly found contaminated housing sites up to 10 miles from the plant.

Horton and colleagues (Inhale Toxicol. 2008;20[8]:767) examined death certificates from 70 sites that received Libby ore; 11 of 70 sites showed an excess of mesothelioma mortality.

Rohs and colleagues (Am J Respir Crit Care Med. 2008;177[5]:689) also describe a 44-year-old man with biopsy-proven asbestosis from tremolite exposure, whose only known exposure was childhood residence near a vermiculite expansion plant.

Given the public health implications of millions environmentally exposed to fibers from vermiculite expansion plants, the Occupational and Environmental Health NetWork invites CHEST 2010 attendees to hear a special presentation by Dr Kelly Duncan—“Is Asbestos From Libby, Montana, More Toxin Than Other Types of Asbestos”—on Sunday, October 31, at 11:15 AM.

Dr Richard Evans, FCCP
Steering Committee Member
New Clinical Resources for Thromboses, Lung Cancer

Evidence-based clinical practice guidelines are important academic contributions but often are not easy to adapt to medical practice. In an effort to assist with the implementation of these guidelines, the ACCP has developed CD-ROM products based on the most recent editions of each of the core guidelines.

Antithrombotic Therapy, 8th ed. The latest version of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines is the most evidence-based edition of these well-respected and much anticipated guidelines.

This clinical resource is a tool kit to access, use, understand, and share the information in the guidelines. This comprehensive resource includes a quick reference guide to all the recommendations in a newer, user-friendly tabular format. All recommendations are included and can be downloaded to PDAs. Patient education materials and 15 sets of PowerPoint slides are also included for your clinical or educational use.

Lung Cancer
The latest recommendations from the 2nd edition of the Diagnosis and Management of Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines have been converted into user-friendly tabular formats to help you help your patients with readily accessible, evidence-based guidance. This CD-ROM contains a quick reference guide based on all of the recommendations, and they are PDA-downloadable.

Other features include 18 sets of PowerPoint slides for presentations to medical and lay audiences and four updated patient education brochures that can be printed for your patients and their families or caregivers.

These clinical resource tool kits can be ordered online at www.chestnet.org. Address questions to Sandra Zelman Lewis, PhD, at slewis@chestnet.org.

CHEST Abstracts Delivered To You. Wherever You Are.

Get monthly CHEST Current Issue abstracts and weekly CHEST Papers in Press abstracts delivered to your Kindle™ e-reader.

Try it free for 2 weeks. Subscribe for a $1.99 monthly fee (per feed).

Current Issue: www.amazon.com/gp/product/B003M1H15C
Papers in Press: www.amazon.com/gp/product/B003M1H184

We took everything you need and put it all in one place.

ACCP Career Connection is your resource for recruiting or finding that ideal position. Use this ACCP member benefit to:

- Find the right jobs.
- Get job alerts.
- Sign up for e-newsletters.
- Read career advice.

Hiring? Put your jobs in front of more job seekers. Take advantage of the redesigned online career center, making it easier than ever to connect with the right candidates.


News from the College

This Month in CHEST: Editor’s Picks

By Dr Richard S. Irwin, Master FCCP
Editor in Chief, CHEST

- Outcomes of Home-Based Diagnosis and Treatment of Obstructive Sleep Apnea. By Dr R. P. Skomor, et al.
- Small- and Moderate-Size Right-to-Left Shunts Identified by Saline Contrast Echocardiography Are Normal and Unrelated to Migraine

CHEST Impact Factor: On the Rise Again

The most recent Journal Citation Report shows that the Impact Factor of CHEST has risen to 6.36, more than a full point higher than last year’s score of 5.15.

This now places CHEST among the top three respiratory journals, an impressive position with CHEST’s dedication to publishing clinically focused research.

CHEST ranks second among 43 respiratory journals by other measures, including number of citations in other journals and the Eigenfactor Score, which is a metric that is the equivalent of Impact Factor with self-citations subtracted.

These numbers are a reflection of the efforts of all of those involved in the peer-review process, the high quality of the work submitted by authors around the globe, and the stewardship of Dr Richard S. Irwin, Master FCCP, Editor in Chief.


Recent Advances in CHEST Medicine

www.chestpubs.org
Disparities in Health Care: Social Injustice and AMI

Beauchamp and Childress defined the major principles of bioethics: beneficence, maleficence, autonomy, and justice (Beauchamp and Childress. Principles of Biomedical Ethics, 5th ed. Oxford, UK: Oxford University Press, 2001). The principle of justice is cited least often. The counterpart of justice, social injustice, is relevant to disparities occurring in the United States, forming the basis for this discussion of health-care disparities observed in patients with acute myocardial infarction (AMI).

Two Institute of Medicine reports stated that health-care quality in the United States is below expectations (To Err Is Human: Building a Safer Health System. Washington, DC: National Academy Press, 2000; Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press, 2001). The IOM drew attention to health-care disparities experienced by rural US residents. Rural residents represent one in five citizens, are distributed throughout 87% of the US, are older, are more likely to have chronic illness, and generally exhibit poor health behaviors, including a reduced commitment to regular exercise (Crossing the Quality Chasm).

Many areas of the United States are not served by a hospital or are serviced by a regional critical access hospital. Critical access hospitals deliver fewer resources than urban facilities, receive less funding, lack staffing by emergency medicine physicians, and are more likely to have chronic illness, and generally exhibit poor health behaviors, including a reduced commitment to regular exercise (Crossing the Quality Chasm).

The scope of social injustice related to rural health care negatively impacts mortality in AMI due to inadequate access to state-of-the-art technology and care. Remote rural areas are often 87% of the United States: a critical lack of access to state-of-the-art technology and care.

Case Examples

Each of these patients experienced a myocardial infarction (AMI). Patient A lives in a large urban metropolitan area and recovered without sequelae. Patient B lives in a rural town and was first transported to a local hospital and, subsequently, to a referral center. Patient C lives in a very rural remote area and received no intervention from the time of awakening with chest pain until arriving at the closest hospital.

Same diagnosis, three different outcomes, with only one of three patients preserved life. These cases are evidence of an all too common but somewhat what well-kept secret in the United States: a critical lack of access to state-of-the-art medical care in rural America. This represents social injustice.

"Justice," said Aristotle, "involves treating like cases alike and different cases differently" (Medicine and Social Justice. Oxford, UK: Oxford University Press, 2002). Patients A, B, and C did not receive equitable treatment. In the late 1990s, there were 134.1 specialists per 100,000 residents in urban counties in the United States, compared with 40.1 per 100,000 in rural counties (Rosenblatt RA and Hart LG. "Physicians and rural America." In: Ricketts TC, ed. Rural Health in the United States. Oxford, UK: Oxford University Press, 1999; 38-31).

Despite the prevalence of evidence-based protocols for treatment of AMI, rural centers are generally less efficient in making a prompt diagnosis and less likely overall to implement evidence-based guideline therapy.

A study published in 2002 evaluating care for AMI among Medicare patients found that these patients treated in rural hospitals were less likely than urban patients to receive aspirin during hospitalization or at discharge, IV nitroglycerin, heparin, and either thrombolytics or percutaneous transluminal coronary angioplasty (Baldwin et al. Quality of Care for Acute Myocardial Infarction in Rural and Urban US Hospitals. Working Paper #72. Seattle, WA: WWAMI Rural Health Research Center, University of Washington; June 2002).

Though the existence of health-care disparities related to access has been acknowledged, effective and meaningful long-term action plans have not yet been instituted. Some suggest that changes are required, beginning with undergraduate medical education (Rabinowitz et al. Acad Medicine. 2008;83[10]:952). Procur ing the right mix of specialty and primary care providers for rural areas will be critically important in addressing rural health-care disparities. Linking rural hospitals and health clinics with tertiary care hospitals via distance technology (telemedicine) systems offers promise. One mechanism that has shown some success is the concept of an e-ICU, which has been shown in preliminary studies to reduce mortality in small rural centers. Widespread implementation of e-ICU services in rural centers has the potential to positively impact diagnostic capabilities and implementation of evidence-based protocols, as well as appropriately timed, sco op-and-run transfers to referral centers.

Continued on following page
Continued from previous page

**Conclusion**

In order to achieve social justice in rural health care, increased access to quality health care by rural residents must be provided. This represents a challenge, particularly in today’s economic and political climate.

Only with increased numbers of appropriately trained primary care providers practicing evidence-based medicine, linked with a network of subspecialist providers, will substantive changes in outcomes begin to occur in rural America.

Rural residents, who account for more than one in five of all US citizens, deserve social justice and access to state-of-the-art health care. Anything less represents social injustice.

Critical care physicians must join together to highlight the injustices experienced by many of the rural residents of our country. Absent such efforts, the health-care community is passively allowing social injustice to continue.

Dr Sandra K. Willies, MA, FCCP
PRA International
Lenexa, KS

---

**PCCSU: New Name Reflects Three Specialties**

Take advantage of this popular, unique education program offered by the ACCP. Each month, a distinguished editorial board of expert clinicians provides two lessons, featuring timely, concise, diagnostic information on current pulmonary, critical care, and sleep medicine issues.

Earn up to 24 AMA PRA Category 1 Credits. TM One credit will be awarded for each completed lesson. Participation is free for ACCP members.

**ACC-P-SEEK for iPhone®, iPad™, and iPod® touch**

A way from your computer but aimed to prepare for the board exams? The ACCP-SEEK App is now available for download over the 3G network. Simply access the App Store from your device, search ACCP-SEEK, and download the App for free. Select individual question sets from the best-selling Pulmonary, Critical Care, and Sleep Medicine editions for $9.99 per set. The iPad version offers enhanced viewing capabilities, including enlarged, expandable images. Learn more at www.chestnet.org/SEEK.

**New for CHEST 2010**

**Meeting Highlights**

- More Than 400 Sessions
- Essential updates on patient care and practice management strategies will be presented to keep you at the forefront of chest medicine.
- **Keynote Speaker**
  - Percussing the Chest in the Era of Homo Technologicus
  - Abraham Verghese, MD, MACP
  - Hear Dr. Verghese relate how preserving the bedside exam may result in cost-effective medical care and be key to the desired therapeutic effect.
- **ACCP Simulation Center**
  - Enhance your learning in a hands-on simulation environment. Featuring simulation exercises in adult tele-ICU, airway management, bronchoscopy, critical care, pulmonary function testing, sleep medicine, and ultrasonography.

**Postgraduate Multipass Courses**

Registration to any postgraduate course will provide a multipass to all postgraduate courses and access to all electronic handouts. Courses include:

- An Integrated and Comprehensive Approach to the Management of Advanced Lung Disease
- Nonpulmonary Issues in the ICU
- Physician Coding, Documentation, and Reimbursement Essentials: Reporting Your Work for Fair and Accurate Reimbursement
- Best of Sleep Medicine 2010 Review of the Literature
- Chest Radiology for the Pulmonologist
- Critical Care Ultrasonography
- Thromboembolic Disease and Pulmonary Hypertension

**August Lessons**

- Thoracic Radiology in the ICU. By Dr Ami N. Rubinowitz; Dr Mark D. Siegel, FCCP; Dr Edward Smitaman; and Dr Mahan Mathur
- Circadian Rhythm Sleep Disorders. By Dr Shirley Feng Jones, FCCP

**Viral Pneumonia.** By Dr Mitsuo Matsuoka; and Dr Richard J. Enelow

**NEWS FROM THE COLLEGE**

**PCCSU: New Name Reflects Three Specialties**

Now available: A Book by Dr. Thomas L. Petty, Master FCCP

**Now Showing on chestnet.org**

A Prospective Multicenter Study of Competency Metrics and Educational Interventions in the Learning of Bronchoscopy Among New Pulmonary Fellows

Access www.drtompetty.org to order.

**ACCP-SEEK® for iPhone®, iPad™, and iPod® touch**

A way from your computer but aimed to prepare for the board exams? The ACCP-SEEK App is now available for download over the 3G network. Simply access the App Store from your device, search ACCP-SEEK, and download the App for free. Select individual question sets from the best-selling Pulmonary, Critical Care, and Sleep Medicine editions for $9.99 per set. The iPad version offers enhanced viewing capabilities, including enlarged, expandable images. Learn more at www.chestnet.org/SEEK.
A Personal Recommendation: Top 5 Vancouver Restaurants

Enjoying a nice meal in Vancouver with family, friends, or colleagues can be the perfect way to experience the city. Need some recommendations? Meet Dr Mark FitzGerald, a Professor of Medicine, University of British Columbia, and Director, Centre for Lung Health, Vancouver, BC, Canada. This Vancouver resident says, “I’m lucky and live in the best place in the world.” Check out some of his favorite Vancouver restaurants.

1. **Le Crocodile.** This is a great French restaurant—never a disappointing meal. $$$ [http://lecrocodilerestaurant.com](http://lecrocodilerestaurant.com)

2. **Bishop’s.** Great Northwestern cuisine is served in a very relaxed and attentive manner. $$$ [www.bishopsonline.com](http://www.bishopsonline.com)

3. **La Régalade.** This is a typical French bistro, only much better than in Paris. La Régalade is on the North Shore but a great place to stop on the way back from a North Shore hike. Reservations are essential. $$$ [www.laregalade.com](http://www.laregalade.com)

4. **Vij’s.** Try the best Indian food outside of India! There are no reservations, but the main restaurant is worth the wait—even the Bollywood stars stand in line. Wait in the snug bar area at the back of the restaurant with great Indian beers and free Indian appetizers. $$$ [www.vij.ca](http://www.vij.ca)

5. **Seasons in the Park.** Enjoy a great location looking over the city with a very reasonably priced menu. $$$ [www.vancouverdine.com/seasonstexperience.aspx](http://www.vancouverdine.com/seasonstexperience.aspx)

Don’t miss CHEST 2010, October 30 – November 4, in Vancouver. Recognized around the world as the authority in clinical chest medicine, CHEST 2010 will feature an essential learning program in pulmonary, critical care, and sleep medicine. Visit [www.acpmeeting.org](http://www.acpmeeting.org) to preview the program and learn more details about the meeting.

FCCPs in the News Near and Far

**Dr Steven E. Weinberger, FCCP**

FacCP has been appointed Executive Vice President and Chief Executive Officer of the American College of Physicians. The selection was made based on a national search and recommendations from a search committee appointed by the ACP Board of Regents. An experienced administrator and board-certified internist and pulmonologist, Dr. Weinberger has served as the ACP Deputy Executive Vice President since 2009 and as the ACP’s Senior Vice President for Medical Education and Publishing since 2004. Prior to joining the ACP, Dr. Weinberger served as faculty associate dean for medical education and professor of medicine at Harvard Medical School.

**Dr Silvia Quadrelli, FCCP**

was recently awarded the Bicentennial Medal from the City of Buenos Aires “in recognition of her lifetime achievements and generous contributions to today’s society.” This is one of Argentina’s most prestigious honors.

Dr. Quadrelli graduated from the University of Buenos Aires in 1979. She holds a degree in Medical Ethics from the Faculty of Social Sciences, a Master’s degree in education, and is completing her Doctorate in Philosophy. She has been an international leader in humanitarian efforts, working with Doctors Without Borders and Doctors of the World from 1982 to 2007.

Overall she has participated in more than 40 international humanitarian aid missions, including leading many large-scale efforts in Kosovo, El Salvador, Argentina, Iraq, Yemen, Sri Lanka, and many other countries.

In addition to her history of holding many leadership positions in national and South American respiratory societies, she is a prior recipient of a CHEST Foundation Governor’s Community Service Award, a Fellow of the American College of Chest Physicians, a member of the ACCP Cultural Diversity NetWork, and a current ACCP Governor for Argentina.

Tobacco Dependence Treatment ToolKit

A Web-Based Resource

Help patients stop smoking with the updated Tobacco Dependence Treatment ToolKit

Easy access to materials and instruments for patient assessment and treatment.

Video presentation on helping your patients comfortably and successfully stop using tobacco.

Multiple search options, so you can quickly find information you need.

Correct coding principles for proper reimbursement.

Help Your Patients Stop—Order Your ToolKit Today

[http://tobaccodependence.chestnet.org](http://tobaccodependence.chestnet.org)

Free lifetime access for ACCP members who order by August 31.

Simplify Your PQRI Reporting

Use PQRIwizard, a new online reimbursement tool to quickly collect, validate, and report quality measure data for the CMS PQRI incentive payment program.

Use the PQRIwizard for the Community-Acquired Pneumonia measure group to:

- Maximize your PQRI incentive.
- Minimize data entry time (requires as few as 30 consecutive patient records).
- Eliminate claims and coding.

Learn More and Register

[www.chestnet.org/accp/quality-improvement/aquire/pqri](http://www.chestnet.org/accp/quality-improvement/aquire/pqri)
**CLASSIFIEDS**

**PROFESSIONAL OPPORTUNITIES**

---

**Forbes and Fortune Small Business Magazine**

*rank Billings, Montana - the Best!*

Practice medicine in a city ranked as one of the Best Small Places for Business and Careers (Forbes, 2009) and the Best Small City in which to start a business (Fortune Small Business Magazine, November 2009).

St. Vincent Healthcare in Billings, Montana seeks a well-trained, compassionate physician for Pulmonology and Critical Care Medicine

- Great practice with maximum flexibility that focuses on quality lifestyle
- Full time or part time position available
- ICU service call: 1:4
- Outpatient Pulmonology clinic: low overhead practice
- Hospitalist program available
- Pediatric Intensive Care Unit staffed 24/7 with Board Certified Pediatric Intensivists
- SVH is staffed for 250 beds
- Regional destination hospital: serves a four-state area and more than 900,000 people each year
- AASM accredited sleep center: Level II Trauma Center; HELP Helicopter and Fixed Wing air transport program with specialty transport teams
- SVH invests in the latest technology
- SVH is ranked Best for Heart Attack Care and #15 for Quality in the nation
- Thriving medical community in a family-oriented suburban location
- Excellent School System
- Abundant recreational activities year round – hiking, skiing, fishing, biking and camping
- Excellent Benefits and Competitive Salary Structure, based on MGMA
- Sign-on Incentives, Moving Allowances, and CME reimbursement.
- Will consider loan forgiveness.

Contact: Colleen Martin at Colleen.Martin@svh-mt.org or 406-237-4003

---

**ADULT INTENSIVISTS**

**Greater Fort Lauderdale, Florida**

Memorial Healthcare System, one of the premier healthcare systems in the nation, is currently seeking to employ an additional full-time, Fellowship Trained Critical Care Medicine Physician to join an established Intensivist Program at Memorial Hospital West.

Ideal candidates are BC/BE pulmonary & critical care trained physicians with good clinical skills and beside manner to manage the care of critically ill patients in our Intensive Care Unit.

We offer an attractive compensation and benefits package and you can be proud to work for an organization recognized by Modern Healthcare Magazine, 2009 as #6 in the Nation for Best Places to Work in Healthcare!

When it comes to lifestyle and career, we have it all... including an average temperature in the high 70’s, miles of beautiful sandy beaches, world class dining, top rated golf courses, professional sporting events, and an abundance of enjoyable activities for the kids.

Diverse housing options, excellent school systems and NO State Income Tax make this an ideal area for business, family, cultural and recreational entertainment!

**Email your CV today to:**

Ken Bolli – (954) 265-9092
Email: mhdctor@mh.net
www.mhhs.net
Visit our website to learn more

---

**Physicians**

**A BALANCED LIFESTYLE:**

**JUST WHAT THE DOCTOR ORDERED**

Successfully balance your career and home life as a VA physician. We have positions available nationwide in both primary care and physician specialties.

VA offers a competitive benefits package that includes:

- 30 days of paid vacation/personal leave
- 13 sick days and 10 holidays
- 15 days of paid military leave
- Family and medical leave
- Liability protection
- Group health insurance plans with the majority of premiums paid by the Federal government
- Term life insurance, family, and additional coverage options
- Stable retirement benefits

For more information, contact:
Roberta Hirneise, Physician Recruiter
roberta.hirneise@va.gov; 352-376-1611, ext. 4278

---

**Moving?**

Look to Classified Notices for practices available in your area.

---

**Advisement**

Chest Physician assumes the statements made in classified advertisements are accurate, but cannot investigate the statements and assumes no responsibility or liability concerning their content. The Publisher reserves the right to decline, withdraw, or edit advertisements. Every effort will be made to avoid mistakes, but responsibility cannot be accepted for clerical or printer errors.
LungPoint®

Virtual Bronchoscopic Navigation Systems

Unparalleled Visualization and Guidance

LungPoint® Virtual Bronchoscopic Navigation highlights the path as you maneuver through airways and guides you directly to your target. Navigate quickly and accurately without proprietary hardware or expensive disposable catheters.

LungPoint Systems are easy to use and affordable. Call today for a hands-on demonstration of LungPoint® VBN – The leading virtual navigation solution, or get started with LungPoint® Planning – The most sophisticated stand-alone planning and virtual guidance solution.

Call or email today:

1-877-428-1600
sales@broncus.com
www.broncus.com